Published in Clin Cancer Res on August 15, 2004
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J Exp Med (2014) 1.49
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A (2009) 1.26
Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. J Biol Chem (2011) 1.10
PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. J Clin Invest (2010) 1.00
Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther (2011) 0.97
Long-term in vivo monitoring of mouse and human hematopoietic stem cell engraftment with a human positron emission tomography reporter gene. Proc Natl Acad Sci U S A (2013) 0.96
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer (2007) 0.93
A deficiency in nucleoside salvage impairs murine lymphocyte development, homeostasis, and survival. J Immunol (2012) 0.90
The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasis. J Biol Chem (2008) 0.88
Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET. J Nucl Med (2012) 0.86
ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice. PLoS One (2009) 0.84
Fast metabolic response to drug intervention through analysis on a miniaturized, highly integrated molecular imaging system. J Nucl Med (2013) 0.83
Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs. Int J Pharm (2010) 0.82
Evaluation of the Genisys4, a bench-top preclinical PET scanner. J Nucl Med (2013) 0.81
Deoxycytidine kinase augments ATM-Mediated DNA repair and contributes to radiation resistance. PLoS One (2014) 0.80
Inhibition of IGF-1 signalling enhances the apoptotic effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One (2011) 0.79
Lipid-based drug carriers for prodrugs to enhance drug delivery. AAPS J (2014) 0.77
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91
Adjuvant docetaxel for node-positive breast cancer. N Engl J Med (2005) 8.00
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 5.80
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood (2007) 5.55
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood (2006) 4.61
Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog (2009) 4.24
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol (2013) 3.67
Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database Syst Rev (2010) 2.35
Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell (2013) 2.35
Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol (2008) 2.31
Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol (2002) 2.23
A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther (2010) 2.10
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res (2004) 2.06
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer (2006) 1.75
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene (2003) 1.73
Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J Med Chem (2008) 1.69
A revised nomenclature for the human and rodent alpha-tubulin gene family. Genomics (2007) 1.68
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology (2012) 1.67
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov (2013) 1.64
The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer (2007) 1.63
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma (2002) 1.61
Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. PLoS One (2009) 1.60
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther (2013) 1.60
Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. Leuk Lymphoma (2007) 1.58
Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res (2005) 1.51
Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther (2005) 1.50
Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer (2004) 1.46
A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells. Int J Cancer (2006) 1.44
Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab. Leuk Lymphoma (2013) 1.43
Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol (2010) 1.43
In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol (2002) 1.37
Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents (2005) 1.35
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther (2011) 1.33
Predictive models for breast cancer susceptibility from multiple single nucleotide polymorphisms. Clin Cancer Res (2004) 1.33
Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther (2009) 1.32
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer (2010) 1.31
Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res (2012) 1.27
Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res (2007) 1.26
The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol (2010) 1.25
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol (2004) 1.23
Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res (2002) 1.20
Interaction of PRMT1 with BTG/TOB proteins in cell signalling: molecular analysis and functional aspects. Genes Cells (2002) 1.16
Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta (2007) 1.16
Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res (2012) 1.12
mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci (2008) 1.11
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer (2002) 1.11
BMP4 regulation of human megakaryocytic differentiation is involved in thrombopoietin signaling. Blood (2008) 1.10
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer (2005) 1.09
Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol (2006) 1.09
Problems related to resistance to cytarabine in acute myeloid leukemia. Leuk Lymphoma (2004) 1.07
STAT3 upregulates the protein expression and transcriptional activity of β-catenin in breast cancer. Int J Clin Exp Pathol (2010) 1.07
The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer (2009) 1.06
Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast (2007) 1.06
Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol (2005) 1.06
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res (2008) 1.02
Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells. Mol Cancer Ther (2011) 1.02
Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. Psychooncology (2010) 1.01
Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol (2008) 1.00
Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol (2003) 1.00
F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells. J Immunol (2010) 1.00
ADP ribosylation factor like 2 (Arl2) protein influences microtubule dynamics in breast cancer cells. Exp Cell Res (2006) 1.00
In vivo model of follicular lymphoma resistant to rituximab. Clin Cancer Res (2009) 0.99
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs (2011) 0.99
Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.98
Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J Immunol (2009) 0.98
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther (2005) 0.97
Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer (2008) 0.97
Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. Med Res Rev (2002) 0.97
Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol (2009) 0.95
Identification of novel markers for the diagnosis of malignant pleural mesothelioma. Am J Pathol (2011) 0.95
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets (2011) 0.94
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemother Pharmacol (2006) 0.94
CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br J Haematol (2008) 0.94
Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104). Int J Cancer (2013) 0.94
Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II issued from virtual screening. Biochem Pharmacol (2012) 0.94
Clinical and biological significance of GSK-3β inactivation in breast cancer-an immunohistochemical study. Hum Pathol (2010) 0.93
Expression of Arl2 is associated with p53 localization and chemosensitivity in a breast cancer cell line. Cell Cycle (2008) 0.92
In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. Biochem Pharmacol (2003) 0.92
Virtual screening and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS One (2012) 0.92
Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem Biophys Res Commun (2008) 0.92